News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis AG (NVS)'s Psoriasis Drug Superior to Amgen (AMGN)'s Enbrel in Study


7/8/2013 7:37:08 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Novartis International AG / Novartis announces secukinumab (AIN457) demonstrated superiority to Enbrel® in head-to-head Phase III psoriasis study. Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

• FIXTURE trial of more than 1,300 moderate-to-severe plaque psoriasis patients showed superiority of secukinumab (AIN457) to Enbrel® (etanercept)

• All primary and secondary endpoints were met - FIXTURE is a pivotal trial for registration; Regulatory submissions for secukinumab (AIN457), a therapy targeting IL-17A, are on track for the second half of 2013

Help employers find you! Check out all the jobs and post your resume.

Read at Market Watch
Read at RTT News
Read at Street Insider
Read at News Release
Read at Reuters

comments powered by Disqus
Novartis AG
Amgen
 
 
Psoriasis

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES